


## Corrections

### BIOCHEMISTRY

Correction for “Purified vitamin K epoxide reductase alone is sufficient for conversion of vitamin K epoxide to vitamin K and vitamin K to vitamin  $\text{KH}_2$ ,” by Pei-Hsuan Chu, Teng-Yi Huang, Jason Williams, and D. W. Stafford, which appeared in issue 51, December 19, 2006, of *Proc Natl Acad Sci USA* (103:19308–19313; first published December 12, 2006; 10.1073/pnas.0609401103).

The authors note that Fig. 5 and its corresponding legend appeared incorrectly. The corrected figure and its corrected legend appear below.

Also, the authors note that on page 19312, right column, 3rd full paragraph, line 5 “The reaction was carried out for 1 hr.” should instead appear as “The reaction was carried out for 20 min.”



**Fig. 5.** Conversion of vitamin K to vitamin  $\text{KH}_2$  by VKOR. The reaction was performed by using purified VKOR that had been dialyzed in the presence of THP. VKOR activity is represented as turnover number per second. Bar 1, DTT with elution buffer as background control; Bar 2, purified VKOR after dialysis against buffer A with 4 mM THP. Data are represented as mean  $\pm$  SD ( $n = 3$ ).

[www.pnas.org/cgi/doi/10.1073/pnas.1401722111](http://www.pnas.org/cgi/doi/10.1073/pnas.1401722111)

### EVOLUTION

Correction for “The Burmese python genome reveals the molecular basis for extreme adaptation in snakes,” by Todd A. Castoe, A. P. Jason de Koning, Kathryn T. Hall, Daren C. Card, Drew R. Schield, Matthew K. Fujita, Robert P. Ruggiero, Jack F. Degner, Juan M. Daza, Wanjun Gu, Jacobo Reyes-Velasco, Kyle J. Shaney, Jill M. Castoe, Samuel E. Fox, Alex W. Poole, Daniel Polanco, Jason Dobry, Michael W. Vandewege, Qing Li, Ryan K. Schott, Aurélie Kapusta, Patrick Minx, Cédric Feschotte, Peter Uetz, David A. Ray, Federico G. Hoffmann, Robert Bogden, Eric N. Smith, Belinda S. W. Chang, Freek J. Vonk, Nicholas R. Casewell, Christiaan V. Henkel, Michael K. Richardson, Stephen P. Mackessy, Anne M. Bronikowski, Mark Yandell, Wesley C. Warren, Stephen M. Secor, and David D. Pollock, which appeared in issue 51, December 17, 2013, of *Proc Natl Acad Sci USA* (110:20645–20650; first published December 2, 2013; 10.1073/pnas.1314475110).

The authors note that the author name Anne M. Bronikowski should instead appear as Anne M. Bronikowski. The corrected author line appears below. The online version has been corrected.

**Todd A. Castoe, A. P. Jason de Koning, Kathryn T. Hall, Daren C. Card, Drew R. Schield, Matthew K. Fujita, Robert P. Ruggiero, Jack F. Degner, Juan M. Daza, Wanjun Gu, Jacobo Reyes-Velasco, Kyle J. Shaney, Jill M. Castoe, Samuel E. Fox, Alex W. Poole, Daniel Polanco, Jason Dobry, Michael W. Vandewege, Qing Li, Ryan K. Schott, Aurélie Kapusta, Patrick Minx, Cédric Feschotte, Peter Uetz, David A. Ray, Federico G. Hoffmann, Robert Bogden, Eric N. Smith, Belinda S. W. Chang, Freek J. Vonk, Nicholas R. Casewell, Christiaan V. Henkel, Michael K. Richardson, Stephen P. Mackessy, Anne M. Bronikowski, Mark Yandell, Wesley C. Warren, Stephen M. Secor, and David D. Pollock**

[www.pnas.org/cgi/doi/10.1073/pnas.1324133111](http://www.pnas.org/cgi/doi/10.1073/pnas.1324133111)

## GENETICS

Correction for “Male-specific region of the bovine Y chromosome is gene rich with a high transcriptomic activity in testis development,” by Ti-Cheng Chang, Yang Yang, Ernest F. Retzel, and Wan-Sheng Liu, which appeared in issue 30, July 23, 2013, of *Proc Natl Acad Sci USA* (110:12373–12378; first published July 10, 2013; 10.1073/pnas.1221104110).

The authors wish to note, “We have recently updated the data associated with our GenBank depositions to include age, tissue, and developmental stage of the bovine testis RNA-seq data. We have also deposited new data for information discussed in the *Supporting Information* of our article. We apologize for not providing this information at the time of publication. The updated accession numbers are as follows:

Accession Number	Sample	Developmental Stage	Tissue
SRX357350	Bos taurus 789_20D	postnatal-20 d	Testis
SRX357349	Bos taurus 789_20D	postnatal-20 d	Testis
SRX357348	Bos taurus 74_8M	puberty-8 mo	Testis
SRX357347	Bos taurus 74_8M	puberty-8 mo	Testis
SRX357346	Bos taurus 645_2Y	maturity-2 y	Testis
SRX357345	Bos taurus 645_2Y	maturity-2 y	Testis
SRX388838	Direct cDNA selection of the bovine Y chromosome		

“In addition, the project ‘Transcriptome analysis of the bovine Y chromosome,’ together with the bovine testis cDNA selection reads and assembled transcripts/ncRNAs (> 200 bp), were submitted to the Transcriptome Shotgun Assembly (TSA) database, [www.ncbi.nlm.nih.gov/genbank/tsa](http://www.ncbi.nlm.nih.gov/genbank/tsa) (Bioproject accession no. PRJNA230872; reads accession no. SRX388838).

“The assembled contigs (> 200 bp) have been deposited at DNA Data Bank of Japan/European Molecular Biology Laboratory/GenBank under the accession GAQO00000000. The version described in this paper is the first version, GAQO01000000.”

[www.pnas.org/cgi/doi/10.1073/pnas.1401739111](http://www.pnas.org/cgi/doi/10.1073/pnas.1401739111)

## IMMUNOLOGY

Correction for “IRAK-1 bypasses priming and directly links TLRs to rapid NLRP3 inflammasome activation,” by Keng-Mean Lin, Wei Hu, Ty Dale Troutman, Michelle Jennings, Travis Brewer, Xiaoxia Li, Sambit Nanda, Philip Cohen, James A. Thomas, and Chandrashekar Pasare, which appeared in issue 2, January 14, 2014, of *Proc Natl Acad Sci USA* (111:775–780; first published December 30, 2013; 10.1073/pnas.1320294111).

The authors note that James A. Thomas should be included as a cocorresponding author. Correspondence can be addressed to him at [james.thomas@bcm.edu](mailto:james.thomas@bcm.edu).

Also, the authors note that they omitted references to articles by Juliana et al. and Fernandes-Alnemri et al. The complete references appear below.

34. Juliana C, et al. (2012) Non-transcriptional priming and deubiquitination regulate NLRP3 inflammasome activation. *J Biol Chem* 287(43):36617–36622.
35. Fernandes-Alnemri T, et al. (2013) Cutting edge: TLR signaling licenses IRAK1 for rapid activation of the NLRP3 inflammasome. *J Immunol* 191(8):3995–3999.

[www.pnas.org/cgi/doi/10.1073/pnas.1401725111](http://www.pnas.org/cgi/doi/10.1073/pnas.1401725111)

# Purified vitamin K epoxide reductase alone is sufficient for conversion of vitamin K epoxide to vitamin K and vitamin K to vitamin KH<sub>2</sub>

Pei-Hsuan Chu\*, Teng-Yi Huang†, Jason Williams‡, and D. W. Stafford\*§

\*Department of Biology, University of North Carolina, Chapel Hill, NC 27599-3280; †Department of Chemistry, Purdue University, West Lafayette, IN 47907; and ‡Laboratory of Structural Biology, National Institute on Environmental Health Sciences, National Institutes of Health, Department of Health and Human Services, 111 T. W. Alexander Drive, Research Triangle Park, NC 27709

Communicated by Earl W. Davie, University of Washington, Seattle, WA, October 27, 2006 (received for review August 8, 2006)

More than 21 million prescriptions for warfarin are written yearly in the U.S. Despite its importance, warfarin's target, vitamin K epoxide reductase (VKOR), has resisted purification since its identification in 1972. Here, we report its purification and reconstitution. HPC4, a calcium-specific antibody that recognizes a 12-aa tag, was used to purify and identify VKOR. Partial reconstitution is achieved on the column by washing with 0.4% dioleoylphosphatidylcholine/0.4% deoxycholate. Activity is completely recovered by dialysis against a buffer containing a reducing agent but lacking dioleoylphosphatidylcholine/deoxycholate. Removal of detergent from the eluted proteins apparently facilitates liposome formation. Purified recombinant VKOR with tag is ≈21 kDa, as expected; fully active; and >93% pure. The concentration of warfarin for 50% inhibition is the same for purified protein and microsomes. It has been reported that VKOR is a multisubunit enzyme. Our results, however, suggest that a single peptide can accomplish both the conversion of vitamin K epoxide to vitamin K and vitamin K to reduced vitamin K. This purification will allow further characterization of VKOR in relation to other components of the vitamin K cycle and should facilitate its structural determination.

purification | reconstitution | membrane protein

In animals, vitamin K is primarily known as a cosubstrate in the posttranslational conversion of glutamate to  $\gamma$ -carboxyglutamate (Gla). There are at least 16 Gla-containing proteins in mammals, and eight of these are related to coagulation. Vitamin K is believed to serve as a precursor to an intermediate that can abstract a proton from the 4-carbon of glutamate to form a carbanion. In turn, this carbanion is attacked by CO<sub>2</sub> to make Gla (1). In the process, vitamin K is converted to vitamin K epoxide, which must be recycled to reduced vitamin K for the next round of reaction (2). The enzyme that catalyzes the conversion of vitamin K epoxide to vitamin K is vitamin K epoxide reductase (VKOR) (3).

VKOR has proved refractory to purification, and thus all characterizations of VKOR to date have been done with purified microsomes. Whitton *et al.* (4) reported detection of VKOR activity in microsomes but not in detergent-solubilized microsomes. Fasco and coworkers reported partial purification of VKOR from rat livers (5); they used cholate to partially solubilize microsomes, followed by separation on a sucrose gradient to isolate a 200 S microsomal subfraction that contained VKOR activity. All attempts at further purification resulted in loss of enzymatic activity; however, a small protein that reacted with radioactive *N*-ethylmaleimide was identified in the 200 S fraction. They conjectured that this small protein was a component of a multiprotein complex that converted vitamin K epoxide to vitamin K. A further purification attempt was reported by Cain *et al.* (6). These authors also concluded that VKOR was a multiprotein complex, and that the two components of this complex were microsomal epoxide hydrolase and GST. However, it was later shown that a mouse knockout of microsomal

epoxide hydrolase had no defect in vitamin K metabolism, and the mouse exhibited no bleeding diathesis (7).

Although both our laboratory (8) and Rost *et al.* (9) reported the identification of the VKOR gene in 2004, purification of its product has remained elusive. Here we report the purification of recombinant human VKOR produced from a baculovirus in insect cells.

## Results

**Purification of VKOR.** Because VKOR is an integral membrane protein, its solubilization from microsomes was necessary for purification. We tested 1,2-dihexanoyl-*sn*-glycero-3-phosphocholine (DHPC), CHAPS, cholate, deoxycholate, Triton X-100, and Nikkol. Preliminary experiments established that DHPC is most effective, meaning that more VKOR remained in the postmicrosomal supernatant after solubilization. The relative amount of VKOR in supernatant and pellet was measured by quantitative Western blotting (data not shown). In addition, the critical micelle concentration of DHPC is relatively high, and it is a mild detergent that helps preserve 3D protein structure and enzymatic activity (10).

Purification is presented in detail in *Materials and Methods*. In summary, a 27-aa tag, which included the 12-aa HPC4 tag (11) and a tandem GGS flexible linker, was attached to the N terminus of VKOR for affinity purification. In addition, the tag was also used to detect VKOR during purification, because solubilization results in loss of enzymatic activity. The monoclonal antibody that recognizes this tag is calcium-specific, binds the tag in the presence of calcium, and releases it when EDTA is added. Because it is difficult to completely solubilize membrane proteins, an extensive wash with DHPC was used to eliminate most contaminating proteins from the affinity resin. Our rationale is that if VKOR within a membrane fragment is bound to HPC4, contaminating proteins that are embedded in the same membrane fragment are washed out by DHPC. It is also important to wash the column with MgATP to remove 70-kDa heat-shock protein, which is commonly associated with denatured protein in the endoplasmic reticulum. A further wash with 0.4% 1,2-dioleoyl-*sn*-glycero-3-phosphocholine (DOPC)/0.4% deoxycholate resulted in partial reconstitution of VKOR activity.

Author contributions: P.-H.C., T.-Y.H., and D.W.S. designed research; P.-H.C., T.-Y.H., J.W., and D.W.S. performed research; J.W. and D.W.S. contributed new reagents/analytic tools; P.-H.C., T.-Y.H., J.W., and D.W.S. analyzed data; and P.-H.C., T.-Y.H., and D.W.S. wrote the paper.

The authors declare no conflict of interest.

Freely available online through the PNAS open access option.

Abbreviations: VKOR, vitamin K epoxide reductase; DHPC, 1,2-dihexanoyl-*sn*-glycero-3-phosphocholine; DOPC, 1,2-dioleoyl-*sn*-glycero-3-phosphocholine; THP, Tris(hydroxypropyl)phosphine.

§To whom correspondence should be addressed. E-mail: dws@email.unc.edu.

© 2006 by The National Academy of Sciences of the USA







## Discussion

In retrospect, the difficulties in purifying VKOR are obvious. All of the detergents that we used to solubilize VKOR also rendered it inactive. One possible reason for this is that the active site (14–16) is embedded in the membrane and may require the membrane structure for activity (12). For this reason, we attached tags at either the N or C terminus to allow purification of VKOR and also to detect its presence during purification. The presumption was that the activity could be recovered after purification. In this study, we used the construct with the N-terminal tag; however, the turnover numbers of purified VKOR for both constructs were similar (data not shown). This suggests that the tag had minimal effect on enzymatic activity.

We tried a number of detergents to determine which were most suitable for solubilization. Western blot analysis was used to select the detergent that left the most VKOR in the supernatant after a  $150,000 \times g_{\text{avg}}$  centrifugation of solubilized microsomes. For solubilization, DHPC was the most effective. Although VKOR activity is nil in the presence of DHPC, after binding to the HPC4 affinity column and extensive washing, activity can be recovered by changing the wash buffer to 0.4% DOPC/0.4% deoxycholate. After elution with EDTA in this buffer, activity is recovered (the enzyme must be diluted at least 10-fold into the reaction mix to measure activity), and the activity is similar to that in microsomes (Fig. 3).

There have been reports that VKOR is a multisubunit enzyme (6); thus, one of the major questions concerning VKOR is, can a single polypeptide accomplish this reaction? To clarify this issue, we tried two approaches. The first was to measure the turnover number of VKOR in microsomes and compare it to the turnover number of purified VKOR. We measured the turnover number in microsome suspensions, because detergents cause activity loss. If VKOR were a multisubunit enzyme, then purification of the product predicted by the identified cDNA (9) would be expected to have a much-reduced turnover number. If an essential component were lost or even much reduced but still present as a contaminant, the turnover number of VKOR in microsomes would be much greater than that of the purified enzyme. However, the turnover number of the dialyzed reduced purified enzyme was actually approximately three times higher than that of VKOR in microsomes (Fig. 3). This increased turnover number provides strong evidence that the single VKOR gene, recently identified by molecular biology techniques (8, 17), codes for the enzyme that converts vitamin K epoxide to vitamin K.

We also tried to eliminate the possibility that any of the minor contaminants seen in our VKOR preparations are related to VKOR function. We concentrated the purified protein and overloaded SDS-NuPAGE gels to identify contaminating proteins. There are several contaminating proteins; however, they are <7% of total purified protein by weight and certainly much less on a molar basis, because VKOR is smaller than any of the contaminants (Fig. 2). Moreover, none of the identified contaminating proteins, sarcoplasmic reticulum-type calcium ATPase, mitochondrial ATP synthase  $\alpha$ - and  $\beta$ -subunits, ribosome-associated protein p40, and nucleopolyhedrovirus protein from the expression vector are likely to contribute to VKOR activity. These contaminants can be minimized by extensive washing but with more extensive washing, VKOR is also lost from the  $\text{Ca}^{2+}$ -dependent monoclonal antibody to human protein C (HPC4 antibody) column.

The increase in turnover number in the purified protein compared with microsomes was somewhat surprising. The active site of VKOR has been proposed to be cysteine residues 132 and 135, and these must be in their reduced form to catalyze the vitamin K epoxide to vitamin K reaction (14–16). Therefore, one possibility for the further increase in turnover number upon

dialysis against buffer containing a reducing agent (DTT or THP) is that these bonds may be in a partially oxidized state and may be converted into the fully active reduced state upon exposure to reducing agent. Another possibility for the increase in turnover number after dialysis with reducing agent is that the insect cells are making more enzyme than can be properly folded. In our case,  $\approx 3\%$  of microsomal protein is recombinant human VKOR. If improper disulfide bonds are formed, they may be rearranged during dialysis in the presence of the reducing agent.

Not only is the turnover number of purified VKOR higher than that measured in microsomes; it is also  $\approx 10$ -fold higher than that of the  $\gamma$ -glutamyl carboxylase (18). Given that VKOR and carboxylase are integral membrane proteins, and that *in vitro* assays are far removed from actual *in vivo* conditions, which at the present are unknown, the VKOR turnover number appears to be adequate for the vitamin K cycle. At this time, we are not able to comment on the report that the chaperonin calumenin is associated with both VKOR and the  $\gamma$ -glutamyl carboxylase and has a role in the vitamin K cycle (19). However, our results argue against the notion that a multicomponent enzyme is required for VKOR activity.

Based on our results, the only activity not provided by purified VKOR is an enzyme to reduce the disulfide form of VKOR to the active reduced form. In our assays, as well as almost all previous work on VKOR, this presumed enzyme is replaced by DTT. The presumed enzyme that re-reduces VKOR *in vivo* is still not known but may be analogous to thioredoxin. In fact, Silverman and Nandi demonstrated that *Escherichia coli* thioredoxin and thioredoxin reductase can stimulate the VKOR reaction in microsomes (20).

We published that VKOR can dramatically increase the fraction of carboxylated factor X produced in HEK 293 cells (13). These results have been confirmed by Wallin's and Berkner's laboratories (21, 22). Because vitamin K is fed to the cells, it seemed reasonable that VKOR was converting vitamin K epoxide to vitamin K and vitamin K to vitamin  $\text{KH}_2$ . Therefore, we tested purified VKOR for its vitamin K to vitamin  $\text{KH}_2$  activity. Our results are clear but preliminary. One difficulty is that the enzyme that converts the oxidized cysteines back to their reduced active forms of VKOR is still not known; therefore, we use DTT in the reaction mix to catalyze the reaction. The problem is that DTT also reduces vitamin K to vitamin  $\text{KH}_2$ . To overcome this obstacle, it was necessary to lower the concentration of the vitamin K substrate so that the chemical conversion by DTT was negligible compared with the enzymatic conversion by VKOR. We have repeated the assay multiple times and are confident that VKOR can catalyze the vitamin K to vitamin  $\text{KH}_2$  reaction. However, we have not yet optimized the reaction. We used the same conditions as for the vitamin K epoxide to vitamin K, so the turnover number is nominal. The observation that VKOR conversion of vitamin K to vitamin  $\text{KH}_2$  is also inhibited by warfarin confirms the necessity of another enzyme such as DT-diaphorase to carry out this conversion when using vitamin K to treat patients with warfarin overdose.

In summary, we have shown that VKOR may be purified as a single peptide, and that this peptide can accomplish the conversion of both vitamin K epoxide to vitamin K and vitamin K to vitamin  $\text{KH}_2$ . Little is known about this reaction mechanism or that of warfarin binding. This purification will allow further characterization and understanding of the VKOR reaction mechanism and its interactions. Perhaps most importantly, the final preparation of active enzyme is very similar to conditions needed to form 2D crystals for electron diffraction studies.

## Materials and Methods

**Chemicals.** All chemicals were reagent grade. The baculovirus viral DNA was purchased from Novagen (Madison, WI). The Sf9

(*Spodoptera frugiperda*) insect cells were obtained from the Lineberger Cancer Center at the University of North Carolina. The HPC4 (11) antibody affinity resin was kindly provided by Charles T. Esmon (Oklahoma Medical Research Foundation, Oklahoma City, OK). Protease inhibitor mixture ( $10 \times$ ) contained 5  $\mu\text{g/ml}$  leupeptin, 7  $\mu\text{g/ml}$  pepstatin A, 20  $\mu\text{g/ml}$  aprotinin (Roche, Boulder, CO). DOPC, and DHPC were from Avanti Polar Lipids (Alabaster, AL). 3-(*N*-morpholino)-propanesulfonic acid (Mops) was from RPI (Mt. Prospect, IL). *N*-[Tris(hydroxymethyl)methyl]-3-aminopropanesulfonic acid, protein standard BSA, warfarin (3-( $\alpha$ -acetylbenzyl)-4-hydroxycoumarin), deoxycholate, and  $\beta$ -hydroxytoluene were from Sigma (St. Louis, MO). The reducing agent THP was from Calbiochem (San Diego, CA). SnakeSkin dialysis tubing was from Pierce (Rockford, IL). PVDF and Microcon YM-10 centrifuge filter devices were from Millipore (Bedford, MA). SYPRO ruby protein gel stain reagent was from Molecular Probes (Eugene, OR). A vitamin K internal standard, 2-methyl-3(3,7,11,15,19-pentamethyl-2-eicosenyl)-1,4-naphthalenedione (K1<sub>(25)</sub>) was from GL Synthesis, Worcester, MA. Vitamin K epoxide was kindly provided by Paul Dowd (University of Pittsburgh, Pittsburgh, PA). Vitamin K1 (phytonadione) was from Abbot (Chicago, IL). ECL Western blotting detection reagents were from Amersham Biosciences (Piscataway, NJ).

**Cloning and Construction of Expression Vector.** The cDNA encoding human VKOR was subcloned into the pVL1392 vector (8). An in-frame coding sequence coding for EDQVDPRLIDGK (GGG)<sub>5</sub> was added to the N or C terminus of VKOR, and the turnover numbers were similar for the two constructs. In this manuscript, the construct with the N-terminal tag was used. The HPC4 tag is underlined; the GGS repeats function as flexible linkers to minimize potential structural perturbation from the affinity tag. The modified cDNA for human VKOR was then subcloned into the BglIII and EcoR I sites of the insect cell expression vector pVL1392. The protein was expressed in baculovirus-infected Sf9 cell, as described (8).

**Preparation of Microsomes.** Microsomes from cells overexpressing VKOR were prepared as described (23). The microsomal pellet was resuspended in 25 mM 3-(*N*-morpholino)-propanesulfonic acid (pH 7.5)/150 mM NaCl containing  $1 \times$  protease inhibitor mixture and 30% glycerol then flash-frozen in liquid nitrogen before storing at  $-80^\circ\text{C}$ .

**Purification of VKOR.** Microsomes were diluted to a final protein concentration of 2 mg/ml total protein in 25 mM 3-(*N*-morpholino)-propanesulfonic acid (pH 7.5)/150 mM NaCl/20% glycerol (buffer A) plus 40 mM DHPC and 4 mM THP. After incubation at  $4^\circ\text{C}$  for 1 hr, the solubilized microsomes were centrifuged at  $150,000 \times g_{\text{avg}}$  for 45 min in a Beckman 70 Ti rotor. Buffer A was made  $1 \times$  protease inhibitor mixture and used to dilute supernatant to a final concentration of 8 mM DHPC. Calcium chloride was added to the supernatant to 2 mM and mixed with the HPC4 resin. The mixture was incubated at  $4^\circ\text{C}$  overnight with gentle rotation. The resin was poured into a column and washed with 10 column volumes of buffer A containing 15 mM DHPC, 10 mM MgATP, 2 mM CaCl<sub>2</sub>, and 4 mM THP. The resin was then washed with 10 column volumes of reconstitution buffer (0.4% DOPC/0.4% deoxycholate/2 mM CaCl<sub>2</sub>/4 mM THP in buffer A). The bound proteins were eluted with buffer A containing 0.4% DOPC/0.4% deoxycholate/10 mM EDTA/4 mM THP then stored at  $4^\circ\text{C}$ .

**Reconstitution by Dialysis.** A further increase in VKOR activity was achieved by dialysis against buffer A in the presence of 4 mM THP at  $4^\circ\text{C}$ . One liter of dialysis buffer was used for each milliliter of purified VKOR, and dialysis was carried out for 96 h

with one buffer change. Another set of experiments was performed by dialyzing against the same buffer but in the absence of the reducing agent THP. At the end of 96-h dialysis, 4 mM THP was added to the dialyzed sample and incubated overnight at  $4^\circ\text{C}$ . The reconstituted protein was stored at  $4^\circ\text{C}$ .

**Quantitation of VKOR.** The concentration of purified VKOR was determined by densitometry analysis. The proteins were separated on reducing SDS-NuPAGE 10% Bis-Tris gel, stained with SYPRO ruby gel stain and visualized by a transilluminator at 300 nm. Concentrations of BSA and VKOR were adjusted so that the signal detected by densitometry was linear. Purified VKOR, whose concentration had been measured as above, was used as a standard for determining VKOR concentrations in microsomes. For this quantification, microsomal proteins were separated by using a reducing SDS-NuPAGE gel and then transferred to a PVDF membrane. The membrane was treated with anti-HPC4 monoclonal antibody followed by a horseradish peroxidase-conjugated secondary antibody and then visualized by the enhanced chemiluminescence Western blot reagent. The data were analyzed by an AlphaImager 2200 (Alpha Innotech, San Leandro, CA).

**VKOR Activity Assay.** VKOR enzymatic activity was assayed (24, 25) with the following modifications. Twenty microliters of microsomes or purified protein was added to 180  $\mu\text{l}$  of buffer B (25 mM *N*-[Tris(hydroxymethyl)methyl]-3-aminopropanesulfonic acid, pH 8.6/150 mM NaCl/30% glycerol). Eight microliters of 5 mM vitamin K epoxide in isopropanol was added as substrate, and 5  $\mu\text{l}$  of 200 mM DTT was added to start the reaction. The reaction mixture was incubated in the dark at  $30^\circ\text{C}$  for 20 min, and the reaction was stopped by adding 500  $\mu\text{l}$  of 0.05 M AgNO<sub>3</sub>:isopropanol (5:9) followed by adding 500  $\mu\text{l}$  of 1.5  $\mu\text{M}$  K1<sub>25</sub> in hexane as an internal standard. The mixture was vortexed for 1 min, followed by brief centrifugation to separate the phases. Four hundred microliters of the upper organic phase was transferred to a 1.8-ml brown vial and dried with a gentle stream of N<sub>2</sub>. Four hundred microliters of the HPLC mobile phase [acetonitrile:isopropanol:water (100:7:2)] was added to dissolve the dried sample. The sample was analyzed by HPLC (Agilent 1100, Agilent Technologies, Austin, TX) on a C-18 column (Vydac, St. Louis, MO; catalog no. 218TP54). Vitamin K production was detected by UV detector at 248 nm.

**Vitamin K Reductase Activity Assay.** The ability of VKOR to convert vitamin K to KH<sub>2</sub> was assayed similarly, except that 2  $\mu\text{l}$  of vitamin K1 (10 mg/ml) was added as a substrate, and 8 pmol of purified enzyme was used. The total reaction volume was 200  $\mu\text{l}$ . The reaction was carried out for 1 hr. At its completion, 500  $\mu\text{l}$  of  $\beta$ -hydroxytoluene was added to stabilize the reduced vitamin KH<sub>2</sub>, and the product was analyzed by HPLC by using fluorescence detector at excitation wavelength 243 nm and emission wavelength at 430 nm.  $\beta$ -Hydroxytoluene does not cause reduction of vitamin K. Controls for background KH<sub>2</sub> formation from DTT were done in the absence of enzyme.

**Warfarin Inhibition.** Twenty microliters of microsomes or purified protein was added to 180  $\mu\text{l}$  of buffer B. Various concentrations of warfarin were added to the samples and preincubated on ice for 10 min. VKOR activity from vitamin K epoxide to vitamin K and vitamin K to vitamin KH<sub>2</sub> was assayed as described above.

We thank Yeu-Fann Stafford, Lee J. Pedersen, Paul Modrich, David Straight, and Sheue-Mei Wu for critical reading of this manuscript. Funding for this work was provided by National Institutes of Health and National Heart, Lung, and Blood Institute Grant 5-R01-HL077740-01.



1. Dowd P, Hershline R, Ham SW, Naganathan S (1995) *Science* 269:1684–1691.
2. Bell RG, Matschiner JT (1972) *Nature* 237:32–33.
3. Willingham AK, Matschiner JT (1974) *Biochem J* 140:435–441.
4. Whitlon DS, Sadowski JA, Suttie JW (1978) *Biochemistry* 17:1371–1377.
5. Lee JJ, Principe LM, Fasco MJ (1985) *Biochemistry* 24:7063–7070.
6. Cain D, Hutson SM, Wallin R (1997) *J Biol Chem* 272:29068–29075.
7. Miyata M, Kudo G, Lee YH, Yang TJ, Gelboin HV, Fernandez-Salguero P, Kimura S, Gonzalez FJ (1999) *J Biol Chem* 274:23963–23968.
8. Li T, Chang CY, Jin DY, Lin PJ, Khvorova A, Stafford DW (2004) *Nature* 427:541–544.
9. Rost S, Fregin A, Ivaskevicius V, Conzelmann E, Hortnagel K, Pelz HJ, Lappegard K, Seifried E, Scharrer I, Tuddenham EG, et al. (2004) *Nature* 427:537–541.
10. Kessi J, Poiree JC, Wehrli E, Bachofen R, Semenza G, Hauser H (1994) *Biochemistry* 33:10825–10836.
11. Stearns DJ, Kurosawa S, Sims PJ, Esmon NL, Esmon CT (1988) *J Biol Chem* 263:826–832.
12. Tie JK, Nicchitta C, von Heijne G, Stafford DW (2005) *J Biol Chem* 280:16410–16416.
13. Sun YM, Jin DY, Camire RM, Stafford DW (2005) *Blood* 106:1–5.
14. Goodstadt L, Ponting CP (2004) *Trends Biochem Sci* 29:289–292.
15. Wajih N, Sane DC, Hutson SM, Wallin R (2005) *J Biol Chem* 280:10540–10547.
16. Rost S, Fregin A, Hunerberg M, Bevans CG, Muller CR, Oldenburg J (2005) *Thromb Haemost* 94:780–786.
17. Rost S, Fregin A, Koch D, Compes M, Muller CR, Oldenburg J (2004) *Br J Haematol* 126:546–549.
18. Lin PJ, Straight DL, Stafford DW (2004) *J Biol Chem* 279:6560–6566.
19. Wajih N, Sane DC, Hutson SM, Wallin R (2004) *J Biol Chem* 279:25276–25283.
20. Silverman RB, Nandi DL (1988) *Biochem Biophys Res Commun* 155:1248–1254.
21. Wajih N, Hutson SM, Owen J, Wallin R (2005) *J Biol Chem* 280:31603–31607.
22. Hallgren KW, Qian W, Yakubenko AV, Runge KW, Berkner KL (2006) *Biochemistry* 45:5587–5598.
23. Wu SM, Morris DP, Stafford DW (1991) *Proc Natl Acad Sci USA* 88:2236–2240.
24. Thijssen HH, Baars LG, Vervoort-Peters HT (1988) *Br J Pharmacol* 95:675–682.
25. Wallin R, Martin LF (1985) *J Clin Invest* 76:1879–1884.